Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy
Status:
Completed
Trial end date:
2017-09-30
Target enrollment:
Participant gender:
Summary
Certain percent of the eyes with proliferative diabetic retinopathymay require pars plana
vitrectomy (PPV) due to vitreous haemorrhage, proliferative membrane, and tractional retinal
detachment. This study will compare intravitreal injection of anti-vascular endothelial
growth factor (ranibizumab) versus sham injection before vitrectomy for PDR. The main focus
is to see if pre-operative injection of ranibizuman can reduce peri-operative hemorrahge
related complications.